Personalized Cancer Therapy
The main goal of this study is to perform standardized testing of tumor tissue to learn which genes are mutated (have changed) to provide personalized cancer therapy options to patients at MD Anderson. Participant's doctor may be able to use testing information on the tumor to identify clinical trials that may be most relevant.
Another goal of this laboratory research study is to learn how often different genes mutate in patients with different cancers. Researchers will also use the information learned from this study to develop a database of the different kinds of mutations in cancer-related genes.
Researchers also hope to better understand how mutations in cancer-related genes may affect a patient's response to different therapies. Researchers can use this information to select specific therapies for future patients that are more likely to be effective.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program|
- Database of Somatic Mutations and Clinical Characteristics [ Time Frame: 20 years ] [ Designated as safety issue: No ]Collection and storage of tumor tissue specimens, blood and/or saliva samples of patients with cancer for somatic mutation analysis for assessing patients that may be eligible for new targeted therapy trials.
Biospecimen Retention: Samples With DNA
|Study Start Date:||March 2012|
|Estimated Primary Completion Date:||March 2032 (Final data collection date for primary outcome measure)|
Patients with histologically or cytologically documented invasive cancer, sarcoma, or hematologic cancer
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01772771
|Contact: Funda Meric-Bernstam, MD||713-792-6940|
|United States, Texas|
|University of Texas MD Anderson Cancer Center/Regional Cancer Centers||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator: Funda Meric-Bernstam, MD|
|Study Chair:||Funda Meric-Bernstam, MD||M.D. Anderson Cancer Center|